<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091632</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1079</org_study_id>
    <secondary_id>NCI-2021-08958</secondary_id>
    <secondary_id>2019-1079</secondary_id>
    <nct_id>NCT05091632</nct_id>
  </id_info>
  <brief_title>Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit</brief_title>
  <official_title>Can You Hear Me? Assessment of Verbal Comprehension and Cognitive Processes in Patients in the Last Days of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the use electroencephalography (EEG - a test that measures brain&#xD;
      waves) to learn if patients who appear unresponsive (do not respond to noises, words, or&#xD;
      touch) retain any consciousness. Families want to know if their loved ones who are&#xD;
      unresponsive can still hear them or feel any discomfort. Information gained from this study&#xD;
      may have important impact in how patients, caregivers, and doctors make decisions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the magnitude of electroencephalography (EEG) response to verbal stimuli among&#xD;
      cancer patients in the last days in life admitted to a palliative and supportive care unit&#xD;
      (PSCU).&#xD;
&#xD;
      II. To examine the feasibility of conducting EEG in cancer patients in the last days of life.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the magnitude of EEG response between impending death cohort and control&#xD;
      cohort.&#xD;
&#xD;
      II. To determine the association between the magnitude of EEG response and clinical&#xD;
      assessments (e.g. JFK Coma Recovery Scale-Revised [CRS-R], Glasgow Coma Scale [GCS], Richmond&#xD;
      Agitation Sedation Scale [RASS], Memorial Delirium Assessment Scale [MDAS]) in impending&#xD;
      death cohort and control cohort separately.&#xD;
&#xD;
      III. To determine the magnitude of EEG response to pressure/noxious stimuli in impending&#xD;
      death cohort and control cohort separately.&#xD;
&#xD;
      IV. To examine serial EEG changes in auditory cortex activation and cognitive processing in&#xD;
      cancer patients over the last days of life.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo EEG over 30 minutes daily until death or discharge and complete&#xD;
      questionnaires over 30 minutes daily until death or discharge to check level of&#xD;
      consciousness, thought, and ability to communicate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of electroencephalography (EEG) response to verbal stimuli among impending death cancer patients</measure>
    <time_frame>Day 1 in palliative and supportive care unit</time_frame>
    <description>The magnitudes of EEG responses in each task will be calculated as the difference between pre-stimulus and post-stimulus, separately. 95% confidence intervals will be estimated for each task.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Locally Advanced Malignant Solid Neoplasm</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <condition>Recurrent Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Observational (EEG, questionnaires)</arm_group_label>
    <description>Patients undergo EEG over 30 minutes daily until death or discharge and complete questionnaires over 30 minutes daily until death or discharge to check level of consciousness, thought, and ability to communicate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroencephalography</intervention_name>
    <description>Undergo EEG</description>
    <arm_group_label>Observational (EEG, questionnaires)</arm_group_label>
    <other_name>EEG</other_name>
    <other_name>electroencephalogram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Observational (EEG, questionnaires)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced cancer admitted to the palliative and supportive care unit at M.D.&#xD;
        Anderson Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BOTH COHORTS: Diagnosis of advanced cancer (defined as locally advanced, metastatic,&#xD;
             recurrent, or incurable disease)&#xD;
&#xD;
          -  BOTH COHORTS: Admitted to the PSCU at MD Anderson Cancer Center&#xD;
&#xD;
          -  IMPENDING DEATH COHORT: Clinician judgement of =&lt; 3 days of survival or &gt;= 1 late sign&#xD;
             of impending death&#xD;
&#xD;
               -  Presence of late signs of impending death are based on reporting by bedside&#xD;
                  nurses, physicians, or research staff. Examples of these signs include inability&#xD;
                  to close eyelids; non-reactive pupils; drooping of nasolabial fold;&#xD;
                  hyperextension of neck; death rattle; grunting of vocal cords; decreased response&#xD;
                  to verbal/visual stimuli; respiration with mandibular movement; Cheyne Stokes&#xD;
                  breathing; pulselessness of radial artery; peripheral cyanosis; or decreased&#xD;
                  urine output&#xD;
&#xD;
          -  IMPENDING DEATH COHORT: Glasgow Coma Scale =&lt; 8&#xD;
&#xD;
          -  IMPENDING DEATH COHORT: Not been able to communicate for past 24 hours (no verbal&#xD;
             response) because of delirium, coma, or impending death based on the judgement of the&#xD;
             palliative care unit physician.&#xD;
&#xD;
          -  IMPENDING DEATH COHORT: Palliative Performance Scale score of 10-20%&#xD;
&#xD;
          -  CONTROL COHORT: Able to communicate for the past 24 hours&#xD;
&#xD;
          -  CONTROL COHORT: Clinician judgement of &gt;= 1 month of survival&#xD;
&#xD;
          -  BOTH COHORTS: English-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BOTH COHORTS: Evidence of brain metastases, brain hemorrhage, or subdural hematomas on&#xD;
             recent neuroimaging&#xD;
&#xD;
          -  BOTH COHORTS: Hearing impairment as documented by chart or requiring hearing aid&#xD;
&#xD;
          -  IMPENDING DEATH COHORT: Mental status changes predominantly related to medications as&#xD;
             per clinician judgement&#xD;
&#xD;
          -  CONTROL COHORT: Diagnosis of delirium (i.e. Memorial Delirium Assessment Scale [MDAS]&#xD;
             &gt;= 13)&#xD;
&#xD;
          -  BOTH COHORTS: Pregnant women&#xD;
&#xD;
          -  BOTH COHORTS: Age &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hui</last_name>
    <phone>713-792-6085</phone>
    <email>dhui@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hui</last_name>
      <phone>713-792-6085</phone>
      <email>dhui@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

